Research Progress on the Prevention and Treatment of Rheumatoid Arthritis (RA)

Yutianle Piao

doi:10.54097/gff9dd26

Authors

Yutianle Piao

DOI:

https://doi.org/10.54097/gff9dd26

Keywords:

Rheumatoid arthritis, interleukin, tumour necrosis factor α.

Abstract

Rheumatoid arthritis (RA) is an autoimmune disease linked to group A type B haemolytic streptococcus infection, characterized by acute fever and migratory joint pain, mainly affecting large joints. Its pathogenesis involves genetics, environmental factors, infections, and immune dysfunction, with symptoms fluctuating due to weather changes. Recent advances in RA treatment include targeted therapy and biological agents, alongside research on immune abnormalities, genetic predisposition, and environmental triggers. Efforts are being made to develop sensitive biomarkers and imaging tools for early diagnosis, as well as promoting multidisciplinary and patient-centered treatment models. However, studies on pediatric RA remain limited, particularly regarding early diagnosis and age-specific treatment strategies. Key findings from literature include: 1) Certain HLA and MHC genes are strongly associated with RA susceptibility; 2) Smoking, air pollution, alcohol, caffeine, and humid-cold environments contribute to RA risk; 3) ESR, CRP, anti-CCP, anti-cyclo-citrulline IgM antibodies, and MRI aid early diagnosis; 4) Adalimumab is effective both alone and in combination with other drugs; 5) Physical therapies like hot/cold compresses and electrotherapy help relieve symptoms. Future research should focus on cost reduction and treatment simplification to improve accessibility and patient outcomes.

Downloads

Download data is not yet available.

References

[1] ABUL KHAIR AHMEDULLAH, SHAMIM AHMED, MD. ABU SHAHIN, MD. ARIFUL ISLAM. Roles of Genes in the Susceptibility to and Severity of Rheumatoid Arthritis [J]. 2012, 13: 51-54.

[2] Liu Wei, Wu Xin, Xu Huji. Research progress on the genetic background of susceptible genes in rheumatoid arthritis [J]. Theory and Practice of Diagnostics, 2018, 17 (3): 347-351.

[3] Yasuto Araki, Toshihide Mimural. The Mechanisms Underlying Chronic Inflammation in Rheumatoid Arthritis from the Perspective of the Epigenetic Landscape [J]. Journal of Immunology Research, 2016.

[4] R. S. Nithyashree, R. Deveswaran. A Comprehensive Review on Rheumatoid Arthritis [J]. Journal of Pharmaceutical Research International, 2020, 32 (12):18-32.

[5] Nithyashree, Deveswaran. A Comprehensive Review on Rheumatoid Arthritis [J]. JPRI, 2020, 32 (12): 18-32. DOI: 10.9734/JPRI/2020/v32i1230377.

[6] Jangampalli Adi Pradeepkiran. Insights of rheumatoid arthritis risk factors and associations [J]. Journal of Translational Autoimmunity, 2019, 2: 100012.

[7] Mahin Lashkari, Akram Noori, Fatemeh Hajiimanouchehri, Sonia Oveisi, Amir Mohammad Kazemifar. Determination of Specificity and Sensitivity of Anti-RA 33 in Diagnosis of Early Rheumatoid Arthritis [J]. Global Journal of Health Science, 2014, 6 (4).

[8] Giuseppe Murdaca, Francesca Spanò, Francesco Puppo. Long-term treatment of rheumatoid arthritis with adalimumab [J]. Open Access Rheumatology: Research and Reviews, 2013.

[9] Mélanie Auréal, Irma Machuca-Gayet, Fabienne Coury. Rheumatoid Arthritis in the View of Osteoimmunology [J]. Biomolecules.

[10] M. Victoria Hernández, Silvia Vidaf, Raimon Sanmarti. Analysis of the Mechanism of Action of Biological Therapies in Monotherapy in Patients with Rheumatoid Arthritis: Beyond the ADACTA Study [J]. Advances in Pharmacoepidemiology & Drug Safety, 2013.

[11] Désirée van der Heijde, Joachim Sieper, Walter P. Maksymowych, et al. Clinical and MRI remission in patients with nonradiographic axial spondyloarthritis who received long-term open-label adalimumab treatment: 3-year results of the ABILITY-1 trial [J]. Arthritis Research & Therapy, 2018, 20: 61. DOI: 10.1186/s13075-018-1556-5.

[12] Josef S. Smolen, Robert B. M. Landewé, Johannes W. J. Bijlsma, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update [J]. Annals of the Rheumatic Diseases, 2019.

[13] Tsutomu Takeuchi, Yoshiya Tanaka, Yuko Kaneko, et al. Effectiveness and safety of adalimumab in Japanese patients with rheumatoid arthritis: retrospective analyses of data collected during the first year of adalimumab treatment in routine clinical practice (HARMONY study) [J]. Modern Rheumatology, 2012, 22: 327-338.

[14] Daniel J. Lovell, Nicolino Ruperto, Richard Mouy, et al. Long-Term Safety, Efficacy, and Quality of Life in Patients with Juvenile Idiopathic Arthritis Treated with Intravenous Abatacept for Up to Seven Years [J]. Arthritis & Rheumatology, 2015, 67 (10).

[15] Calenzi, Marco Marucci Erinic, Clodoveo Turi, et al. Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab because of side effects [J]. Annals of the Rheumatic Diseases, 2007, 66: 249-252. DOI: 10.1136/ard.2006.058776.

[16] Louis Bessette, Majed Khraishi, Alan J. Kivitz, et al. Single-Arm Study of Etanercept in Adult Patients with Moderate to Severe Rheumatoid Arthritis Who Failed Adalimumab Treatment [J]. Rheumatology and Therapy, 2017, 4: 391-404. DOI: 10.1007/s40744-017-0079-x.

[17] Martin Perry, Andrew McGucken. The potential value of blood monitoring of biologic drugs used in the treatment of rheumatoid arthritis [J]. Therapeutic Advances in Musculoskeletal Disease, 2020, 12: 1-13.

[18] Syamsudin, Arti Dwi Astuti. Literature Review: Pengaruh Simplisia Jahe terhadap Penurunan Nyeri Rheumatoid Arthritis [J]. Jurnal Keperawatan, 2021, 7 (2): 37-48.

[19] Tianhong Liu, Zhaojun Song, Shenchen Qiu. The effect of transdermal acupoint electrical stimulation on the expression level of peripheral opioid peptide in rheumatoid arthritis rats [J]. Shanghai Journal of Acupuncture and Moxibustion, 2021.